Abstract:
Objectives: To determine demographics, clinical variables, difference in vaccination type and outcomes associated with psoriasis flares following COVID-19 vaccination. Materials and Methods: We recruited all patients, who had visited psoriasis clinic at King Chulalongkorn Memorial Hospital during 2018 2021 whom we could reach, totaling 176. The exacerbation of psoriasis was evaluated by telephone self-report questionnaire. A flare of psoriasis was defined from 4 aspects including number of lesions, redness, itch, and morphological changes. Patient baseline clinical characteristic, comorbidities, type of vaccination and other trigger factors including smoking, alcohol intake, pregnancy and stress were also collected. Results: Psoriasis flare following COVID-19 vaccination was observed 28% from self-report questionnaire. The exacerbation of psoriasis was 15%, 18% and 15% from inactivated, viral vector and mRNA vaccine, respectively. Flare onset ranged from 1 day to 14 days. Most of the patients experienced favorable outcomes, with improvement within 3 days to 4 months. One patient showed morphologic change from plaque-type to pustular psoriasis. The deterioration of psoriasis was not statistically associated with baseline characteristic, comorbidities, current treatment, and type of vaccination. Conclusion: Psoriasis flare was reported as an adverse event following covid-19 vaccination with no statistically association to vaccination type. However, most of the patients experienced self-limited resolution.